Abstract
ObjectiveTo evaluate whether nocturnal asymptomatic hypoglycemia (NAH) can be predicted by fasting glucose levels or post-breakfast glucose fluctuations in patients with type 1 diabetes (T1D) receiving insulin degludec.MethodsPatients with T1D receiving insulin degludec underwent at-home CGM assessments. Indices for glycemic variability before and after breakfast included fasting glucose levels and the range of post-breakfast glucose elevation. For comparison, the patients were classified into those with NAH and those without. The optimal cut-off values for the relevant parameters were determined to predict NAH using ROC analysis.ResultsThe study included a total of 31 patients (mean HbA1c values, 7.8 ± 0.7%), and 16 patients (52%) had NAH. Those with NAH had significantly lower fasting glucose levels than did those without (82 ± 48 mg/dL vs. 144 ± 69 mg/dL; P = 0.009). The change from pre- to post-breakfast glucose levels was significantly greater among those with NAH (postprandial 1-h, P = 0.028; postprandial 2-h, P = 0.028). The cut-off values for prediction of NAH were as follows: fasting glucose level <84 mg/dL (sensitivity 0.80/specificity 0.75/AUC 0.80; P = 0.004), 1-h postprandial elevation >69 mg/dL (0.75/0.67/0.73; P = 0.033), and 2-h postprandial elevation >99 mg/dL (0.69/0.67/0.71; P = 0.044).ConclusionsThe results suggest that fasting glucose level of < 84 mg/dL had approximately 80% probability of predicting the occurrence of NAH in T1D receiving insulin degludec. It was also shown that the occurrence of hypoglycemia led to greater post-breakfast glucose fluctuations and steeper post-breakfast glucose gradients.
Highlights
The aims of diabetes treatment are preventing the onset and progression of diabetic complications through glycemic and metabolic control and maintaining quality of life (QOL) and lifespan for affected individuals
The results suggest that fasting glucose level of < 84 mg/dL had approximately 80% probability of predicting the occurrence of nocturnal asymptomatic hypoglycemia (NAH) in type 1 diabetes (T1D) receiving insulin degludec
It was shown that the occurrence of hypoglycemia led to greater post-breakfast glucose fluctuations and steeper post-breakfast glucose gradients
Summary
The aims of diabetes treatment are preventing the onset and progression of diabetic complications through glycemic and metabolic control and maintaining quality of life (QOL) and lifespan for affected individuals. “the lower the HbA1c, the better the prognosis” does not necessarily apply to patients with type 1 diabetes, who are reportedly at a greater (rather than smaller) risk of allcause and cardiovascular mortality even when their HbA1c values are controlled to 6.9% or lower [5]. This is likely due to the increased risk of hypoglycemia associated with tight glycemic control aimed at lowering HbA1c [6,7,8]. Serious hypoglycemia is shown to significantly increase the risk for mortality among patients with type 1 and type 2 diabetes alike, irrespective of their history of cardiovascular disease [20]
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have